Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06742190 · ClinicalTrials.gov registry record · Phase 3
A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor Neuropathy
A Phase 3 study of Multifocal Motor Neuropathy (MMN) and MMN, sponsored by argenx.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 115
- Enrollment target
- 20
- Study locations
NCT06742190: Recruiting Phase 3 study of Multifocal Motor Neuropathy (MMN) and MMN, sponsored by argenx.
NCT06742190 is a Phase 3 study of Multifocal Motor Neuropathy (MMN) and MMN that is actively recruiting participants, run by argenx. The registered enrollment target is 115 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (85% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06742190, a Phase 3 study of Multifocal Motor Neuropathy (MMN) and MMN, is actively recruiting participants, sponsored by argenx.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 115 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of this study is to compare empasiprubart and IVIg in adult patients with MMN. The study consists of a double-blinded part A (empasiprubart, IVIg) and an open-label part B (empasiprubart). The maximum study duration for participants is up to 49 months. More information can be found here: https://clinicaltrials.argenx.com/empassion
Conditions Studied
Interventions
- BIOLOGICAL Empasiprubart
- BIOLOGICAL IVIG (Intravenous Immunoglobulin)
- OTHER Empasiprubart-placebo
- OTHER IVIg-placebo
Study Locations (20)
Florida
- EZR Research LLC - Boca Raton
- Healthcare Innovations Institute, LLC - Coral Springs
- University of Miami Miller School of Medicine - Miami
- University of South Florida - Tampa
California
- The Neurology Group - Pomona
- Samir Macwan, M.D., Inc. - Rancho Mirage
- University of California San Francisco - San Francisco
Maryland
- Perelman Center for Advanced Medicine - Columbia
- UC Irvine - MDA ALS and Neuromuscular Center - Columbia
New York
- Dent Neurologic Institute Amherst - Amherst
- Columbia University Medical Center - New York
Arizona
- HonorHealth Neurology - Bob Bove Neuroscience Institute - Neurology - Scottsdale
Colorado
- University of Colorado - Anschutz Cancer Pavilion (Neuro Onc Clinic) - Aurora
Connecticut
- Yale University School of Medicine - New Haven
District of Columbia
- Medstar Health Research Institute - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 115 participants |
| Start Date | 2024-12-18 |
| Est. Completion | 2029-12 |
| Phase | Phase 3 |
What NCT06742190 shows while recruiting
NCT06742190 is an interventional study that assigns participants to a tested intervention. The registered 115 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (85% lower).
The record links to 2 conditions, with Multifocal Motor Neuropathy (MMN) appearing as the primary indexed condition, and to 4 interventions - of which Empasiprubart is the first listed.
NCT06742190 names 20 study sites across 13 states, led by Florida, California, Maryland.
Frequently Asked Questions
What is clinical trial NCT06742190 about?
NCT06742190 is a clinical study titled "A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor Neuropathy". The main purpose of this study is to compare empasiprubart and IVIg in adult patients with MMN. The study consists of a double-blinded part A (empasiprubart, IVIg) and an open-label part B (empasiprubart). The maximum study duration for participants is up to 49 months. More information can be found...
What is the current status of trial NCT06742190?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 115 participants. The study started on 2024-12-18. Estimated completion is 2029-12.
What conditions does trial NCT06742190 study?
This clinical trial studies the following conditions: Multifocal Motor Neuropathy (MMN), MMN.
What interventions are being tested in trial NCT06742190?
The interventions under investigation include: Empasiprubart (BIOLOGICAL), IVIG (Intravenous Immunoglobulin) (BIOLOGICAL), Empasiprubart-placebo (OTHER), IVIg-placebo (OTHER).
Who is sponsoring clinical trial NCT06742190?
This trial is sponsored by argenx, which has 49 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06742190 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multifocal Motor Neuropathy (MMN)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06742190's enrollment target sits among peer trials
115 1645th of 2000 higher than 353 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02346929 · 115 participants · NA
Hematoma Block for Distal Radius Fracture
- NCT03394365 · 115 participants · Phase 3
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
- NCT03907475 · 115 participants · Phase 2
Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial
- NCT05086692 · 115 participants · Phase 1
A Beta-only IL-2 ImmunoTherapY Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI